Graftys was incepted in 2005 by three business-driven executives of the orthopedic industry and an academic Research Director in the field of synthetic biomaterials, leading a renowned Research Unit in Nantes.
The Company is headed by Aurélien Valet, CEO and Chairman, a seasoned pharma and biot entrepreneur.
Graftys has implemented a hybrid business model combining a worldwide commercial activity and a strong R&D platform in liaison with the French Academic Research.
Graftys’ mission is to become a major player in the design, manufacturing and commercialization of synthetic bone biomaterials.
To achieve that goal, Graftys has developed an innovation-driven growing pipeline through partnerships with leading academic research institutions in Europe and has progressively built a portfolio aimed at addressing specific and unmet patients’ medical needs.
Graftys commercializes its first generation of products in more than 25 countries, including the United States.